Contrasting Medpace (NASDAQ:MEDP) and AIkido Pharma (NASDAQ:AIKI)

Medpace (NASDAQ:MEDP) and AIkido Pharma (NASDAQ:AIKI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations.

Profitability

This table compares Medpace and AIkido Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Medpace 12.11% 16.05% 10.08%
AIkido Pharma N/A -88.61% -83.62%

Valuation & Earnings

This table compares Medpace and AIkido Pharma’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Medpace $860.97 million 4.91 $100.44 million $3.02 39.52
AIkido Pharma $10,000.00 3,876.12 -$4.18 million N/A N/A

Medpace has higher revenue and earnings than AIkido Pharma.

Institutional & Insider Ownership

79.8% of Medpace shares are owned by institutional investors. Comparatively, 0.9% of AIkido Pharma shares are owned by institutional investors. 26.0% of Medpace shares are owned by company insiders. Comparatively, 4.2% of AIkido Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Medpace has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, AIkido Pharma has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Medpace and AIkido Pharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medpace 0 3 2 0 2.40
AIkido Pharma 0 0 0 0 N/A

Medpace presently has a consensus price target of $97.67, indicating a potential downside of 18.17%. Given Medpace’s higher possible upside, equities research analysts plainly believe Medpace is more favorable than AIkido Pharma.

Summary

Medpace beats AIkido Pharma on 10 of the 11 factors compared between the two stocks.

Medpace Company Profile

Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its drug development services include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.

AIkido Pharma Company Profile

AIkido Pharma Inc., a biotechnology development company, focuses on developing small-molecule anti-cancer therapeutics. The company engages in the development of therapeutic drugs for the treatment of pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Its portfolio includes KPC-34 for the treatment of AML and ALL; and DHA-dFdC drug for the treatment of pancreatic cancer. AIkido Pharma Inc. has an artificial intelligence and machine learning research agreement with Cogia Biotech LTD. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2020. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.